Cagrilintide: A Literature Course in Six Modules

This six-module course summarises the published literature on cagrilintide. It describes what researchers did, what endpoints they measured, and what they reported — nothing more. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or decision. Every module closes with an explicit statement of the limits of the evidence, because the boundaries of a dataset matter as much as its findings.

Module 1 — What Cagrilintide Is and How It Has Been Studied

Definition and class

Cagrilintide is a synthetic, long-acting analogue of human amylin, a pancreatic hormone. A medicinal-chemistry paper in the Journal of Medicinal Chemistry described the design and development of cagrilintide as a long-acting amylin analogue, including the sequence modifications and lipid side-chain acylation intended to extend its duration of action to support once-weekly subcutaneous administration (PMID 34288673). A narrative review in Cardiology in Review classified cagrilintide as a long-acting amylin analogue investigated for the treatment of obesity and described it as acting at amylin and calcitonin receptors (PMID 36883831).

Forms that appear in the literature

Across the published trials, cagrilintide was administered as a once-weekly subcutaneous injection, either as a single agent or coadministered with the GLP-1 receptor agonist semaglutide — the fixed-dose combination referred to in the literature as cagrilintide–semaglutide, or CagriSema. A phase 1b trial evaluated multiple escalating doses of cagrilintide given concomitantly with semaglutide 2.4 mg once weekly for 20 weeks in people with overweight or obesity (PMID 33894838). Later phase 2 and phase 3 programmes used cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly (PMID 37364590, PMID 40544433).

Map of the published studies

Limits of the evidence in Module 1

The published record is concentrated in weight-management and type 2 diabetes populations recruited into industry-sponsored trials. There is no verified literature here on oral, intranasal or topical cagrilintide, no long-term registry data, and no published comparison of cagrilintide against every other amylin-pathway compound.

Module 2 — Mechanism as Described in the Literature

The amylin pathway

Amylin is described in the review literature as a hormone co-secreted with insulin that contributes to satiety signalling, and cagrilintide was characterised there as a long-acting agonist at amylin and calcitonin receptors developed to engage that pathway for weight management (PMID 36883831). The development paper framed the molecule's acylation and sequence changes as a strategy to obtain sustained receptor engagement compatible with weekly dosing rather than to change the receptor target itself (PMID 34288673).

Receptor-level and circuit-level work

A 2025 EBioMedicine study reported that cagrilintide lowered body weight through brain amylin receptors 1 and 3, implicating central rather than purely peripheral receptor populations in the weight effect observed in its preclinical models (PMID 40609154). A 2026 Nature Metabolism paper built a cross-species atlas of the dorsal vagal complex and reported neural mediators of the effects of cagrilintide on energy balance, situating the compound's activity within hindbrain circuits that integrate feeding and satiety signals (PMID 42260119).

Why combination studies exist

The clinical programme tested cagrilintide alongside semaglutide on the rationale that amylin-receptor and GLP-1-receptor signalling are distinct, and the phase 1b trial was designed to examine whether concomitant administration altered pharmacokinetics or tolerability (PMID 33894838).

Limits of the evidence in Module 2

The receptor and circuit findings come from animal models and tissue atlases; they describe mechanism in those systems and do not establish that the same circuits account for every clinical observation in humans. No verified human imaging or human neural-recording study of cagrilintide appears in this course.

Module 3 — Reported Outcomes by Study

Phase 1b: tolerability and coadministration

The phase 1b trial administered multiple doses of cagrilintide with semaglutide 2.4 mg once weekly over 20 weeks and reported safety, tolerability, pharmacokinetic and pharmacodynamic results as its stated objectives, with the combination judged by the investigators to warrant further study (PMID 33894838).

Phase 2 dose-finding in overweight and obesity

A multicentre, randomised, double-blind, placebo-controlled and active-controlled phase 2 trial evaluated once-weekly cagrilintide at doses from 0.3 mg to 4.5 mg over 26 weeks in people with overweight and obesity, with liraglutide 3.0 mg as the active comparator (PMID 34798060). The study reported dose-dependent mean percentage reductions in body weight across the cagrilintide groups, with the 4.5 mg group reaching approximately −10.8% compared with about −3.0% in the placebo group and about −9.0% with liraglutide 3.0 mg at week 26 (PMID 34798060).

Phase 2 in type 2 diabetes

A phase 2, multicentre, randomised, double-blind, active-controlled trial of once-weekly cagrilintide 2.4 mg coadministered with once-weekly semaglutide 2.4 mg in type 2 diabetes reported greater reductions in HbA1c and body weight with the combination than with the comparator regimens over the trial period (PMID 37364590).

Phase 3: REDEFINE 1 and REDEFINE 2

In the phase 3 trial of coadministered cagrilintide and semaglutide in adults with overweight or obesity, researchers reported a mean body-weight change of roughly −20% with the combination versus roughly −3% with placebo at week 68 (PMID 40544433). The companion phase 3 trial in adults with overweight or obesity and type 2 diabetes reported greater reductions in body weight and in glycated haemoglobin with cagrilintide–semaglutide than with placebo over the same trial duration (PMID 40544432).

Secondary and pooled analyses

A secondary analysis of REDEFINE 1 published in Hypertension reported reductions in blood pressure among adults with overweight or obesity receiving cagrilintide–semaglutide (PMID 41328546). A systematic review and meta-analysis of cagrilintide alone and in combination with semaglutide pooled randomised data on efficacy and safety as anti-obesity medications (PMID 39676787), and a later meta-analysis with GRADE assessment compared CagriSema against semaglutide monotherapy or placebo and reported the certainty of evidence for its pooled weight outcomes (PMID 41759565).

Limits of the evidence in Module 3

These are group means from randomised trials with defined inclusion criteria, comparator choices and follow-up windows; they are not individual predictions. Trial durations ran to 68 weeks at most in the verified set, endpoints were weight, glycaemia and blood pressure rather than mortality or cardiovascular events, and the pooled analyses inherit the heterogeneity of their source trials.

Module 4 — Cagrilintide Side Effects: What Studies Report

Gastrointestinal events dominate the published record

In the phase 2 dose-finding trial, the most frequently reported adverse events with once-weekly cagrilintide at 0.3–4.5 mg were gastrointestinal, most commonly nausea, and most were described by the investigators as mild to moderate (PMID 34798060). The phase 2 trial in type 2 diabetes similarly reported gastrointestinal adverse events as the most common category with cagrilintide 2.4 mg coadministered with semaglutide 2.4 mg (PMID 37364590).

Phase 3 and pooled safety reporting

The phase 3 trial in adults with overweight or obesity reported that gastrointestinal adverse events were more frequent with coadministered cagrilintide and semaglutide than with placebo, and that most such events were mild or moderate in severity (PMID 40544433). The phase 3 trial in participants with type 2 diabetes also reported gastrointestinal adverse events as the leading category in the combination groups (PMID 40544432). Pooled analyses reached the same qualitative conclusion: the meta-analysis of cagrilintide alone and with semaglutide reported an increase in gastrointestinal adverse events relative to comparators (PMID 39676787), and the GRADE-assessed meta-analysis reported higher rates of gastrointestinal adverse events with CagriSema than with semaglutide monotherapy or placebo (PMID 41759565).

Early-phase tolerability

The phase 1b trial listed safety and tolerability among its primary objectives and reported that concomitant administration of multiple cagrilintide doses with semaglutide 2.4 mg was tolerated over 20 weeks, with gastrointestinal events among those recorded (PMID 33894838). The Cardiology in Review summary of the development programme likewise described gastrointestinal effects as the principal tolerability issue reported for the amylin analogue class in obesity trials (PMID 36883831).

Limits of the evidence in Module 4

Adverse-event counts reflect trial populations who were screened, monitored and often subject to gradual dose escalation; rates in other settings need not match. Rare events, events emerging after 68 weeks, and events in groups excluded from these trials cannot be estimated from this literature. Reported tolerability for the combination cannot be separated cleanly into single-agent contributions in every analysis.

Module 5 — Pharmacokinetics Where Data Exist

The most direct human pharmacokinetic data in the verified set come from the phase 1b trial, which listed pharmacokinetics and pharmacodynamics among its objectives for multiple doses of cagrilintide administered with semaglutide 2.4 mg over 20 weeks and supported continued once-weekly dosing of the combination (PMID 33894838). The development paper described the molecular strategy — analogue design with a lipid side chain — that was intended to produce the protracted exposure profile behind that weekly schedule (PMID 34288673). Clinically, the once-weekly interval was carried forward into the phase 2 dose-finding trial (PMID 34798060) and the phase 3 programme (PMID 40544433).

Limits of the evidence in Module 5

The verified literature does not provide population pharmacokinetic modelling across organ-impairment groups, drug-interaction studies beyond coadministration with semaglutide, or comparative bioavailability data for alternative routes of administration. Any numeric half-life, clearance or volume-of-distribution figure circulating outside these papers is not supported by the sources in this course.

Module 6 — Regulatory Status, Stated Factually

Cagrilintide has been studied as an investigational compound. The papers in this course describe phase 1b, phase 2 and phase 3 randomised trials of cagrilintide alone and coadministered with semaglutide (PMID 33894838, PMID 34798060, PMID 40544433), and the review literature characterised it as a candidate under development for obesity rather than an established therapy (PMID 36883831).

Separately from the science, several regulatory facts are worth stating plainly:

• Material sold with research-use-only (RUO) labelling is designated for laboratory research and is labelled as not for human or veterinary use; RUO status is a labelling and distribution category, not an approval.
• In the United States, pharmacy compounding of a drug from a bulk substance is governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which restrict which bulk drug substances may be used; substances that are components of investigational products do not automatically qualify.
• Regulatory status differs by jurisdiction and changes over time, so the current status of any product should be checked against the relevant regulator's own published records.

This module summarises general regulatory categories for educational purposes and is not legal advice.

Limits of the evidence in Module 6

Peer-reviewed trial publications report science, not marketing authorisations; none of the cited papers is a regulatory decision document. Approval decisions, labelling and enforcement priorities are set by agencies and can change after any paper is published.

What the Studies Did Not Test

Reading the verified literature as a whole, several questions remain outside it:

• Durability beyond the trial window. The longest randomised follow-up in this set ran to 68 weeks (PMID 40544433); what happens over many years, or after discontinuation, was not characterised.
• Hard clinical outcomes. Endpoints were body weight, glycaemia, blood pressure and adverse events (PMID 41328546), not cardiovascular events, kidney outcomes or mortality.
• Populations outside inclusion criteria. Children, pregnancy and lactation, and people excluded for comorbidity were not studied in these trials (PMID 40544432).
• Non-obesity indications. The verified clinical literature addresses weight management and type 2 diabetes only (PMID 39676787).
• Mechanistic translation. Brain amylin-receptor and dorsal vagal complex findings were generated in animal and cross-species tissue work (PMID 40609154, PMID 42260119), not in human interventional mechanism studies.
• Non-clinical use contexts. No paper in this set evaluated unsupervised use, non-pharmaceutical material, or administration outside a monitored trial protocol.

Anyone with a clinical question about amylin analogues should raise it with a licensed physician; this course exists to describe the published record, not to guide use.

References

• Development of Cagrilintide, a Long-Acting Amylin Analogue (Journal of Medicinal Chemistry, 2021)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial (Lancet, 2021)
• Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (Lancet, 2021)
• Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity (Cardiology in Review, 2024)
• Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (Lancet, 2023)
• Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis (Indian Journal of Endocrinology and Metabolism, 2024)
• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2025)
• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (New England Journal of Medicine, 2025)
• Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 (EBioMedicine, 2025)
• CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 (Hypertension, 2026)
• CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment (American Journal of Cardiology, 2026)
• A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance (Nature Metabolism, 2026)